Mikafungin Accord (Micafungin)

Micafungin is an echinocandin antifungal indicated for serious Candida infections and for prophylaxis in high‑risk patients.

• Invasive candidiasis: effective treatment to eradicate bloodstream and deep‑tissue Candida infections.
• Esophageal candidiasis: resolves mucosal infection and associated pain in immunocompromised patients.
• Candidemia: clears Candida organisms from the bloodstream, reducing mortality risk.
• Prophylaxis in hematopoietic stem cell transplantation: prevents invasive fungal infections during the neutropenic phase.

• Micafungin inhibits the enzyme β‑1,3‑D‑glucan synthase, which is essential for synthesis of β‑(1,3)‑D‑glucan, a critical component of the fungal cell wall. By blocking this pathway, the drug weakens the cell wall, leading to osmotic instability and fungal cell lysis. The mechanism is selective for fungal cells, resulting in minimal impact on human cells.

Micafungin may cause a range of adverse reactions, most of which are related to its intravenous administration and its effect on fungal cell walls.

Common Side Effects

• Infusion‑related reactions: flushing, rash, or mild hypotension during or shortly after administration.
• Gastrointestinal disturbances: nausea, vomiting, or abdominal discomfort.
• Elevated liver enzymes: transient increases in ALT or AST levels.
• Headache: mild to moderate intensity, often self‑limiting.

Serious or Rare Side Effects

• Severe hypersensitivity: anaphylaxis or angioedema requiring immediate medical attention.
• Hepatotoxicity: marked elevation of liver enzymes or bilirubin indicating liver injury.
• Renal impairment: acute kidney injury or worsening of pre‑existing renal dysfunction.
• Hematologic abnormalities: neutropenia or thrombocytopenia observed in some patients.

When using Micafungin, clinicians should consider several precautionary measures to ensure safe and effective therapy.

• Renal function: assess baseline creatinine and monitor during treatment in patients with renal impairment.
• Hepatic function: evaluate liver enzymes before initiation and periodically thereafter.
• Concomitant hepatotoxic drugs: avoid or use with caution when combined with other agents that affect liver function.
• Pregnancy and lactation: use only if the potential benefit outweighs potential risk, as safety data are limited.
• Drug interactions: review concomitant medications for known interactions, especially with cytochrome P450 substrates.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the vial.

Micafungin can interact with other medicines, altering its efficacy or increasing toxicity.

Major Interactions (Avoid)

• Cytochrome P450 3A4 inducers (e.g., rifampicin, carbamazepine): may significantly reduce micafungin plasma concentrations.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can increase micafungin exposure, raising risk of toxicity.

Moderate Interactions (Monitor Closely)

• Immunosuppressants (e.g., tacrolimus, cyclosporine): may require dose adjustment and therapeutic drug monitoring.
• Statins metabolized by CYP3A4 (e.g., simvastatin): monitor for increased statin levels and muscle toxicity.
• Anticoagulants (e.g., warfarin): observe INR values as micafungin may affect anticoagulant effect.